TRANSGENE (EPA:TNG) | WebDisclosure

PRESS RELEASE

published on 06/03/2024 at 07:30, 2 years 2 months ago

Transgene – Premier patient inclus dans la partie Phase II de l’étude randomisée de Phase I/II de son actif phare TG4050, un vaccin thérapeutique individualisé évalué dans les cancers de la tête et du cou
Transgene annonce l'inclusion du premier patient dans la partie Phase II de l'étude randomisée de Phase I/II pour son vaccin TG4050 dans les cancers de la tête et du cou. Démarrage de la sélection des patients pour cette étude internationale

Cancer De La Tête Et Du Cou Étude Clinique Transgene Vaccin Thérapeutique Néoantigènes
PRESS RELEASE

published on 06/03/2024 at 07:30, 2 years 2 months ago

Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
Transgene enrolls first patient in Phase II of randomized Phase I/II trial for cancer vaccine TG4050 in head and neck cancer, with completion expected in Q4 2025

Phase II Trial Head And Neck Cancer Cancer Vaccine Transgene TG4050
BRIEF

published on 05/14/2024 at 17:50, 2 years 3 months ago

Transgene Announces Positive Q1 2024 Update and Future Clinical Milestones

Clinical Trials Financial Update Cancer Immunotherapy Transgene TG4050
BRIEF

published on 05/14/2024 at 17:50, 2 years 3 months ago

Transgene annonce une mise à jour positive pour le premier trimestre 2024 et de futures étapes cliniques

Essais Cliniques Mise À Jour Financière Immunothérapie Anticancéreuse Transgene TG4050
PRESS RELEASE

published on 05/14/2024 at 17:45, 2 years 3 months ago

Transgene provides business and financial update for Q1 2024
Transgene provides business and financial update for Q1 2024, including promising Phase I data on TG4050 and upcoming clinical data expectations on TG4001, TG6050, and BT-001 in H2 2024

Clinical Data Q1 2024 Financial Update Transgene TG4050
PRESS RELEASE

published on 05/14/2024 at 17:45, 2 years 3 months ago

Transgene fait le point sur ses activités et sa situation financière au premier trimestre 2024
Point sur les activités et la situation financière de Transgene au premier trimestre 2024, avec des données prometteuses de Phase I pour TG4050 et des prévisions de nouvelles données cliniques pour TG4001, TG6050 et BT-001

Biotechnologie Santé Financière Immunothérapie Transgene TG4050

Published on 08/20/2026 at 00:40, 3 minutes ago

Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program
Published on 08/19/2026 at 22:00, 2 hours 43 minutes ago

Jaguar Health Reports Second Quarter 2026 Financials
Published on 08/19/2026 at 20:35, 4 hours 8 minutes ago

Revive Therapeutics Announces Proposed Shares for Debt Settlement
Published on 08/19/2026 at 18:50, 5 hours 53 minutes ago

AmeriTrust Auto Advances End-to-End Lease Remarketing Strategy
Published on 08/19/2026 at 16:00, 8 hours 43 minutes ago

Telefónica Chile and Amdocs Establish Strategic Multi-Year Agreement to Accelerate Modernization and Business Agility in Chile

View all ACCESSWIRE

Published on 08/19/2026 at 18:45, 5 hours 58 minutes ago

NNS acquires shares in OCI
Published on 08/19/2026 at 18:00, 6 hours 43 minutes ago

Dividend Declaration
Published on 08/19/2026 at 17:37, 7 hours 6 minutes ago

Monthly Performance Factsheet
Published on 08/19/2026 at 16:51, 7 hours 52 minutes ago

AUTODOC and Apollo Funds successfully conclude transformative partnership
Published on 08/19/2026 at 16:15, 8 hours 28 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc

View all EQS

Published on 08/18/2026 at 18:00, 1 day 6 hours ago

KLARSEN : Nomonation Olivier Cornelis DG ITL et webinaire
Published on 08/18/2026 at 17:45, 1 day 6 hours ago

Mise à disposition du rapport financier annuel 2025-26
Published on 08/18/2026 at 11:15, 1 day 13 hours ago

GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 10 au 14 août 2026
Published on 08/18/2026 at 11:15, 1 day 13 hours ago

GUILLEMOT CORPORATION | Weekly report share buyback from August 10 to August 14 2026
Published on 08/17/2026 at 19:45, 2 days 4 hours ago

Aéroports de Paris S.A - July 2026 traffic figures

View all LES ECHOS COMFI WIRE

News